Lilly: when "better than expected" isn't better enough

Investment Analysis Clubs Macro Economic Trends and Risks
1

The company posted good results, and raised guidance, but the stock was whacked about 14%

But their weight loss drug in pill form doesn’t perform quite as well as a jab, and some could not tolerate the side effects.

And then there is his nibs’ promise to cut drug prices by 1500%

Steve

3 Likes
2

I pay around $50 a month for my asthma inhaler. I figure if he can cut that price by 1500% I’ll be adding another $750 a month to my Social Security.

Sweet!

5 Likes